Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo

被引：22

作者：

Dracinska, Helena ^{[1
]}

Barta, Frantisek ^{[1
]}

Levova, Katerina ^{[1
]}

Hudecova, Alena ^{[1
]}

Moserova, Michaela ^{[1
]}

Schmeiser, Heinz H. ^{[2
]}

Kopka, Klaus ^{[2
,3
]}

Frei, Eva ^{[1
]}

Arlt, Volker M. ^{[4
]}

Stiborova, Marie ^{[1
]}

机构：

[1] Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, CZ-12840 Prague, Czech Republic

[2] German Canc Res Ctr, Div Radiophannaceut Chem, Heidelberg, Germany

[3] German Canc Consortium DKTK, Heidelberg, Germany

[4] Kings Coll London, MRC PHE Ctr Environm & Hlth, Analyt & Environm Sci Div, London WC2R 2LS, England

来源：

TOXICOLOGY | 2016年 / 344卷

关键词：

Aristolochic acid I; Cytochromes P450 1A1 and 1A2; Oxidative detoxification; Reductive activation; DNA adducts; P-32 POSTLABELING ANALYSIS; METABOLIC-ACTIVATION; REDUCTIVE ACTIVATION; NAD(P)H/QUINONE OXIDOREDUCTASE; UROTHELIAL CANCER; O-DEMETHYLATION; RISK-FACTOR; SUDAN-I; NEPHROPATHY; DETOXICATION;

D O I：

10.1016/j.tox.2016.01.011

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aristolochic acid I (AAI) is a natural plant alkaloid causing aristolochic acid nephropathy, Balkan endemic nephropathy and their associated urothelial malignancies. One of the most efficient enzymes reductively activating AAI to species forming AAI-DNA adducts is cytosolic NAD(P)H:quinone oxidoreductase 1. AAI is also either reductively activated or oxidatively detoxified to 8-hydroxyaristolochic acid (AAIa) by microsomal cytochrome P450 (CYP) 1A1 and 1A2. Here, we investigated which of these two opposing CYP1A1/2-catalyzed reactions prevails in AAI metabolism in vivo. The formation of AAI-DNA adducts was analyzed in liver, kidney and lung of rats treated with AAI, Sudan I, a potent inducer of CYP1A1/2, or AAI after pretreatment with Sudan I. Compared to rats treated with AAI alone, levels of AAI-DNA adducts determined by the P-32-postlabeling method were lower in liver, kidney and lung of rats treated with AAI after Sudan I. The induction of CYP1A1/2 by Sudan I increased AAI detoxification to its O-demethylated metabolite AAIa, thereby reducing the actual amount of AAI available for reductive activation. This subsequently resulted in lower AAI-DNA adduct levels in the rat in vivo. Our results demonstrate that CYP1A1/2-mediated oxidative detoxification of AAI is the predominant role of these enzymes in rats in vivo, thereby suppressing levels of AAI-DNA adducts. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：7 / 18

页数：12

共 65 条

[1] Aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? [J].

Arlt, VM ;

Ferluga, D ;

Stiborova, M ;

Pfohl-Leszkowicz, A ;

Vukelic, M ;

Ceovic, S ;

Schmeiser, HH ;

Cosyns, JP .

INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (05) :500-502

[2] Aristolochic acid as a probable human cancer hazard in herbal remedies: a review [J].

Arlt, VM ;

Stiborova, M ;

Schmeiser, HH .

MUTAGENESIS, 2002, 17 (04) :265-277

[3] Aristolochic acid mutagenesis:: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer [J].

Arlt, Volker M. ;

Stiborova, Marie ;

vom Brocke, Jochen ;

Simoes, Maria L. ;

Lord, Graham M. ;

Nortier, Joelle L. ;

Hollstein, Monica ;

Phillips, David H. ;

Schmeiser, Heinz H. .

CARCINOGENESIS, 2007, 28 (11) :2253-2261

[4] The Hepatic Reductase Null (HRN™) and Reductase Conditional Null (RCN) mouse models as suitable tools to study metabolism, toxicity and carcinogenicity of environmental pollutants [J].

Arlt, Volker M. ;

Henderson, Colin J. ;

Wolf, C. Roland ;

Stiborova, Marie ;

Phillips, David H. .

TOXICOLOGY RESEARCH, 2015, 4 (03) :548-562

[5] Role of P450 1A1 and P450 1A2 in Bioactivation versus Detoxication of the Renal Carcinogen Aristolochic Acid I: Studies in Cyp1a1(-/-), Cyp1a2(-/-), and Cyp1a1/1a2(-/-) Mice [J].

Arlt, Volker M. ;

Levova, Katerina ;

Barta, Frantisek ;

Shi, Zhanquan ;

Evans, James D. ;

Frei, Eva ;

Schmeiser, Heinz H. ;

Nebert, Daniel W. ;

Phillips, David H. ;

Stiborova, Marie .

CHEMICAL RESEARCH IN TOXICOLOGY, 2011, 24 (10) :1710-1719

[6] CYTOCHROME-P450 SPECIFICITIES OF ALKOXYRESORUFIN O-DEALKYLATION IN HUMAN AND RAT-LIVER [J].

BURKE, MD ;

THOMPSON, S ;

WEAVER, RJ ;

WOLF, CR ;

MAYER, RT .

BIOCHEMICAL PHARMACOLOGY, 1994, 48 (05) :923-936

[7] Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry [J].

Chan, Wan ;

Cui, Liang ;

Xu, Guowang ;

Cai, Zongwei .

RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2006, 20 (11) :1755-1760

[8] Inhibition of Renal NQO1 Activity by Dicoumarol Suppresses Nitroreduction of Aristolochic Acid I and Attenuates its Nephrotoxicity [J].

Chen, Min ;

Gong, Likun ;

Qi, Xinming ;

Xing, Guozhen ;

Luan, Yang ;

Wu, Yuanfeng ;

Xiao, Ying ;

Yao, Jun ;

Li, Yan ;

Xue, Xiang ;

Pan, Guoyu ;

Ren, Jin .

TOXICOLOGICAL SCIENCES, 2011, 122 (02) :288-296

[9] The Epidemiology, Diagnosis, and Management of Aristolochic Acid Nephropathy A Narrative Review [J].

Goekmen, M. Refik ;

Cosyns, Jean-Pierre ;

Arlt, Volker M. ;

Stiborova, Marie ;

Phillips, David H. ;

Schmeiser, Heinz H. ;

Simmonds, Monique S. J. ;

Cook, H. Terence ;

Vanherweghem, Jean-Louis ;

Nortier, Joelle L. ;

Lord, Graham M. .

ANNALS OF INTERNAL MEDICINE, 2013, 158 (06) :469-477

[10] Aristolochic acid and the etiology of endemic (Balkan) nephropathy [J].

Grollman, Arthur P. ;

Shibutani, Shinya ;

Moriya, Masaaki ;

Miller, Frederick ;

Wu, Lin ;

Moll, Ute ;

Suzuki, Naomi ;

Fernandes, Andrea ;

Rosenquist, Thomas ;

Medverec, Zvonimir ;

Jakovina, Krunoslav ;

Brdar, Branko ;

Slade, Neda ;

Turesky, Robert J. ;

Goodenough, Angela K. ;

Rieger, Robert ;

Vukelic, Mato ;

Jelakovic, Bojan .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (29) :12129-12134

← 1 2 3 4 5 6 7 →